옵션 체인은 다양한 행사가격과 만기일에 대한 Simulations Plus의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Simulations Plus에 대한 시장 심리를 평가합니다..

Simulations Plus (NASDAQ:SLP) 주식, 옵션 체인

Simulations Plus

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Biotech

Government

News

Regulations

Health Care

After-Hours Center

Movers

ABSI

CERT

RXRX

SDGR

미국 식품의약국(FDA)이 동물실험 의무 조항을 단계적으로 폐지할 계획을 발표했다. 이에 목요일(10일) 장 마감 후 헬스케어 기술 분야의 여러 주식이 상승세를 보이고 있다.

美FDA, 동물실험 의무 조항 단계적 폐지 발표...헬스케어 기술 주식 급등

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

금요일(4일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다. 금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

Small Cap

LEVI

주식선물이 이번 목요일 아침 미국에서 상승하면서, 오늘 투자자들의 주목을 끌 수 있는 몇 가지 주식은 다음과 같습니다.

월스트리트는 Conagra Brands, Inc.(NYSE:CAG)의 오프닝벨 전에 1주당 65센트의 분기 실적과 301억달러의 매출을 발표할 것으로 예상하고 있습니다. 이는벤징가 프로의 데이터에 따른 것입니다. Conagra 주식은 매출 후 시간에 1.2% 상승하여

리바이스, 콘아그라 브랜즈와 목요일로 향하는 3종목의 주식

Simulations Plus Inc

Smooth Love Potion - United States Dollar

SIMPLEX HLDGS INC by SIMPLEX HLDGS INC.

Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the industry-leading software and consulting service expertise to successfully implement the FDA roadmap.

Simulations Plus Supports FDA's Plan to Reduce Animal Testing with New Approach Methodologies

Keybanc analyst Scott Schoenhaus maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight and raises the price target from $32 to $40.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $40

WIIM

ABCL

Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 300 points on Friday.
The Dow traded up 0.78% to 39,903.35 while the NASDAQ gained 1.14% to 16,573.81. The S&amp;P 500 also rose, gaining, 0.92% to 5,316.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44757629/top-2-consumer-stocks-that-may-collapse-this-quarter">Top 2 Consumer Stocks That May Collapse This Quarter</a>
Leading and Lagging Sectors Information technology shares surged by 1.2% on Friday.
In trading on Friday, consumer discretionary shares fell by 1%.
Top Headline
The University of Michigan consumer sentiment dipped to 50.8 in April, recording the weakest level since June, compared to 57 in March.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) shares shot up 77% to $1.4101 after the company secured $2 million non-dilutive financing.</li>
<li>Shares of MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>)got a boost, surging 89% to $2.4099. On Thursday, the company entered into a strategic term sheet with Hazel Partners, Virage Capital and affiliates to execute a series of restructuring initiatives.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares were also up, gaining 21% to $31.18. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares dropped 52% to $2.39 after the company announced exercise of warrants for $1.8 million gross proceeds.</li>
<li>Shares of Steel Partners Holdings L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLP#NYSE">SPLP</a>) were down 15% to $31.15 as the company reported voluntary NYSE delisting and SEC deregistration.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) was down, falling 13% to $3.1050. Evercore ISI Group analyst Duane Pfennigwerth maintained Frontier Group with an In-Line rating and lowered the price target from $7 to $5.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $60.50 while gold traded up 2.5% at $3,257.80.
Silver traded up 4.3% to $32.08 on Friday, while copper rose 4.8% to $4.5460.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.10%, Germany's DAX 40 fell 0.92% and France's CAC 40 slipped 0.30%. Spain's IBEX 35 Index fell 0.18%, while London's FTSE 100 rose 0.64%.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 dipping 2.96%, China's Shanghai Composite gaining 0.45%, Hong Kong's Gang Seng index rising 1.13% and India's BSE Sensex jumping 1.77%.
Economics
<ul>
<li>U.S. producer prices fell 0.4% month-over-month in March compared to a 0.1% gain in the previous month.</li>
<li>The University of Michigan consumer sentiment dipped to 50.8 in April, recording the weakest level since June, compared to 57 in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44758556/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

Intraday Update

LUCY

MSPR

SPLP

ULCC

Gold Gains Over 2%; US Consumer Sentiment Dips In April

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">traditional animal testing</a>.
The agency aims to adopt human-relevant and technologically advanced testing methods to improve safety evaluations, reduce research costs and accelerate drug development timelines.
The FDA&#8217;s new approach, <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs" rel="noreferrer noopener">outlined</a> in a roadmap released on Thursday, encourages drug developers to integrate New Approach Methodologies (NAMs), including AI-driven simulations and laboratory-based human models.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44761003/sony-nintendo-hike-console-prices-as-us-tariffs-bite-microsoft-may-dodge-the-hit" rel="noreferrer noopener">Sony, Nintendo Hike Console Prices As US Tariffs Bite, Microsoft May Dodge The Hit</a>
These alternatives are expected to provide more accurate predictions of human responses and toxicities, which can be difficult to detect through animal testing alone.
One key strategy promoted in the roadmap is the use of advanced computer modeling.
AI-based simulations can mimic how monoclonal antibodies travel through the human body and predict potential side effects based on the drug&#8217;s structure. The FDA believes this could significantly reduce the reliance on animals in preclinical studies.
In addition, the agency is supporting the use of lab-grown human organoids and organ-on-a-chip technologies.
These systems replicate the function of human organs like the liver and heart, offering a more precise picture of how a drug might behave in the human body.
Such human-based models have the potential to detect adverse effects that may not surface in animal studies.
To incentivize the adoption of these methods, the FDA plans to update regulatory guidelines and offer streamlined reviews for applications supported by NAMs data.
This could shorten development timelines and lower the cost of bringing monoclonal antibody therapies to market.
The agency will also begin using real-world safety data from countries with comparable regulatory standards, particularly for drugs already tested in humans abroad.
This marks another step toward reducing redundant animal testing while maintaining rigorous safety standards.
The FDA is working to validate and expand these alternative methods in collaboration with federal agencies such as the National Institutes of Health and the Department of Veterans Affairs.
A public workshop is scheduled later this year to gather feedback from stakeholders on the roadmap&#8217;s rollout.
Over the next year, the FDA will pilot a program allowing select developers to rely primarily on non-animal testing methods for monoclonal antibody development.
William Blair writes that even though these changes will be rolled out gradually over time, drug developers will still want to do at least some animal testing. This may be a major overhang for Charles River Laboratories International, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), which generates roughly 20% of its revenue from testing drugs in non-human primates. The stock plunged over 20% on Thursday.
Analyst Max Smock adds that the move can be potentially favorable to Certara Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) and Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), both of which have preclinical models that can be used in place of or in conjunction with animal-based testing.
CRL, CERT, SLP Price Actions: Charles River stock is down 1.84% at $96.68, Certara stock is up 13.5% at $11.96 and Simulations Plus stock is up 22.80% at $31.61 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" target="_blank" rel="noreferrer noopener">Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Large Cap

General

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday.
Shares of Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) rose sharply during Thursday's session following better-than-<a href="https://www.benzinga.com/news/earnings/25/04/44761872/fastenal-beats-revenue-estimates-in-q1-but-margins-narrow-as-costs-rise">expected first-quarter sales.</a>
Fastenal on Friday reported first-quarter 2025 revenue of $1.959 billion, a 3.4% year-over-year increase and slightly above the $1.95 billion consensus estimate. Adjusting for one less selling day and the absence of Good Friday in March, net daily sales grew 5.0%.
Fastenal shares jumped 3.3% to $78.31 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares jumped 30.3% to $14.52.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 28% to $5.77.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) rose 19.3% to $30.72. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 16.2% to $28.26.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 15.2% to $2.8300.</li>
<li>Schrödinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) gained 13.6% to $21.84.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 13.55% to $32.07.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) rose 12.6% to $11.84. Baird analyst Joe Vruwink maintained Certara with a Neutral and raised the price target from $9 to $13.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 12% to $8.18.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) gained 10.6% to $230.00.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) gained 10.6% to $28.11.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) rose 8.5% to $42.15.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) jumped 7.6% to $9.72.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44759875/mckesson-to-rally-more-than-11-here-are-10-top-analyst-forecasts-for-friday">McKesson To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday</a> </li>
</ul>
Photo via Shutterstock

AMRN

CBLL

FAST

NMAX

ZLAB

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares increased by 124.2% to $2.87 during Friday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 31.69% to $0.02. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares moved upwards by 22.17% to $31.45. The company's market cap stands at $632.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock rose 20.43% to $7.77. The company's market cap stands at $5.8 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock moved upwards by 18.36% to $12.44. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) stock moved upwards by 17.74% to $2.19. The market value of their outstanding shares is at $162.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) shares declined by 38.0% to $1.5 during Friday's pre-market session. The company's market cap stands at $117.4 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 35.26% to $0.18. The market value of their outstanding shares is at $1.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 31.64% to $0.29. The company's market cap stands at $7.5 million. </li>
<li>KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) shares fell 29.39% to $1.61. The market value of their outstanding shares is at $74.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) stock declined by 24.78% to $1.64. The market value of their outstanding shares is at $2.9 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock declined by 23.08% to $8.0. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATX

KRMD

MESO

NAOV

ONVO

PHLT

STSS

YCBD

12 Health Care Stocks Moving In Friday's Pre-Market Session

JPM: 4% &#x7C; <a href="https://www.benzinga.com//node/44757891">JPMorgan Chase shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.</a>
&nbsp;
SLP: 28% &#x7C; <a href="https://www.benzinga.com//node/44751076">Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</a>
&nbsp;
MSPR: 200% &#x7C; <a href="https://www.benzinga.com//node/44754787">MSP Recovery To Eliminate $1.2B In Liabilities Through Strategic Partnerships And Creation Of Independent Servicer</a>

Market-Moving News for April 11th

Shares of argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and <a href="https://www.benzinga.com/quote/ARGX">chronic inflammatory demyelinating polyneuropathy.</a>
argenx shares jumped 5.1% to $573.88 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) rose 167% to $3.43 in pre-market trading as the company announced strategic term sheet providing prospective liquidity and restructuring of existing agreements to remove corporate guaranteed debt by over $1.2 billion as well as new agreements aimed at driving future growth.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) surged 73.6% to $0.0318 in pre-market trading after jumping 30% on Thursday.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) gained 26.5% to $0.3300 in pre-market after dipping 22% on Thursday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) rose 26.4% to $0.8198 in pre-market trading. Actelis Networks recently announced it received a new order to modernize Orange County&#8217;s traffic infrastructure.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) rose 25.6% to $5.10 in pre-market trading. Venus Concept announced closing of $1.1 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) gained 21.7% to $7.90 in pre-market trading.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) jumped 19.1% to $5.37 in pre-market trading.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) surged 18.1% to $12.41 in pre-market trading after gaining 8% on Thursday.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) gained 13.7% to $29.23 in pre-market trading. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>AlTi Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) fell 57.3% to $1.20 in pre-market trading after declining around 6% on Thursday.</li>
<li>cbdMD, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#NYSE">YCBD</a>) shares tumbled 38.9% to $0.1701 in pre-market trading. CbdMD announced shareholder approval of automatic conversion of series a preferred stock and other results from annual meeting.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 32% to $4.01 in today's pre-market trading.</li>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares fell 27.1% to $1.59 in pre-market trading.</li>
<li>Palatin Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) fell 16.8% to $0.3510 in pre-market trading after the company announced it received a NYSE American notice of delisting.</li>
<li>Betterware de México, S.A.P.I. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) shares fell 24% to $8.21 in pre-market trading. Betterware de México will report its first quarter results after the U.S. market close on Thursday, April 24.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) shares dipped 22.3% to $2.20 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 14.9% to $2.35 in pre-market trading.</li>
<li>Costamare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) dipped 14.3% to $7.42 in pre-market trading after falling 5% on Thursday.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) declined 12.8% to $6.62 in pre-market trading after falling 5% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

ALTI

ARGX

ASNS

BOOM

BWMX

CMRE

INNV

MAZE

NEXA

SLSR

VERO

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to <a href="https://www.benzinga.com/fda-calendar">phase out animal testing requirements</a>.
What Happened: The FDA on Thursday announced plans to replace&nbsp;animal testing in the development of monoclonal antibody therapies and other drugs with human-relevant methods.
The FDA said it will phase out animal testing requirements in favor of AI-based computational models of toxicity and cell lines and organoid toxicity testing. Implementation is expected to begin immediately.
Health care tech and AI-powered biotech stocks making the biggest moves after the bell include Certara Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>), Schrodinger Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>), Simulations Plus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>). All of the aforementioned names were up between 15% and 25% in Thursday&#8217;s after-hours session at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,&#8221; said Martin Makary, commissioner of the FDA.
&#8220;By leveraging AI-based computational modeling, human organ model-based lab testing and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&amp;D costs and drug prices.&#8221;
The policy changes will help improve the overall process by introducing advanced computer simulations, human-based lab models and regulatory incentives. The change is also expected to result in faster drug development. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44751312/wall-street-on-edge-bank-earnings-inflation-data-consumer-sentiment-set-stage-for-friday-fireworks">Wall Street Braces For High-Stakes Friday With Bank Earnings, Inflation Data, Consumer Sentiment In Focus</a></li>
</ul>
Photo: Tada Images/Shutterstock.

Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 36.7% to $5.55 during Thursday's after-market session. The company's market cap stands at $3.6 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares moved upwards by 31.03% to $2.36. The company's market cap stands at $5.9 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares rose 30.27% to $2.84. The company's market cap stands at $5.1 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock moved upwards by 26.67% to $13.44. The company's market cap stands at $2.1 billion. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) stock moved upwards by 24.7% to $32.1. The company's market cap stands at $645.5 million. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock rose 20.61% to $5.44. The company's market cap stands at $2.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock fell 27.0% to $1.03 during Thursday's after-market session. The company's market cap stands at $34.7 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares fell 26.34% to $0.31. The company's market cap stands at $8.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock fell 13.77% to $4.29. The market value of their outstanding shares is at $10.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 13.29% to $0.38. The market value of their outstanding shares is at $2.0 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 10.86% to $5.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares declined by 9.72% to $0.25. The market value of their outstanding shares is at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELZ

NIVF

NOTV

12 Health Care Stocks Moving In Thursday's After-Market Session

Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

<a href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs#:~:text=Today%2C%20the%20U.S.%20Food%20and,effective%2C%20human%2Drelevant%20methods" title="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs#:~:text=Today%2C%20the%20U.S.%20Food%20and,effective%2C%20human%2Drelevant%20methods">https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs#:~:text=Today%2C%20the%20U.S.%20Food%20and,effective%2C%20human%2Drelevant%20methods</a>.

'FDA Announces Plan to Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs' - FDA

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 1,100 points on Friday. Beijing unveiled a retaliatory 34% tariff on U.S. goods—mirroring the rate announced by President Donald Trump on Wednesday—deepening fears of a full-blown trade war.
The Dow traded down 4.03% to 38,909.97 while the NASDAQ fell 4.94% to 15,733.18. The S&amp;P 500 also fell, dropping, 4.79% to 5,138.01.
Check This Out: <a href="https://www.benzinga.com/25/04/44644881/top-3-financial-stocks-that-may-fall-off-a-cliff-in-april">Top 3 Financial Stocks That May Fall Off A Cliff In April</a>
Leading and Lagging Sectors Real estate shares fell by just 2.9% on Friday.
In trading on Friday, energy shares tumbled by 7.3%.
Top Headline
In March, nonfarm payrolls surged by 228,000, the Bureau of Labor Statistics reported Friday. The outcome is well above the three-month average of 195,000 and topped economists&#8217; forecasts of 135,000. February's employment growth was downwardly revised to 117,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares shot up 7% to $0.7943. XChange TEC.INC announced the acquisition of a Hong Kong-based insurance brokerage firm licensed by the Hong Kong Insurance Authority.</li>
<li>Shares of Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>)got a boost, surging 6% to $25.13 as the company posted stronger-than-expected results for its second quarter and issued upbeat FY25 earnings forecast.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) shares were also up, gaining 15% to $7.46.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares dropped 44% to $0.4852 following its $8 million stock offering.</li>
<li>Shares of Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) were down 23% to $29.39.</li>
<li>Nabors Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) was down, falling 21% to $29.06.</li>
</ul>
Commodities In commodity news, oil traded down 7.6% to $61.88 while gold traded down 2.3% at $3,049.80.
Silver traded down 6.9% to $29.77 on Friday, while copper fell 8.1% to $4.4360.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 5.12%, Germany's DAX 40 dipped 4.95% and France's CAC 40 fell 4.26%. Spain's IBEX 35 Index fell 5.83%, while London's FTSE 100 dipped 4.95%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 dipping 2.75% and India's BSE Sensex falling 1.22%.
Economics
<ul>
<li>In March, nonfarm payrolls surged by 228,000, the Bureau of Labor Statistics reported Friday. The outcome is well above the three-month average of 195,000 and topped economists&#8217; forecasts of 135,000. February's employment growth was downwardly revised to 117,000.</li>
<li>The unemployment rate unexpectedly inched higher from 4.1% to 4.2%, defying expectations for no change.</li>
<li>Average hourly earnings increased 0.3% from February&#8217;s pace, as predicted, and rose 3.8% year-over-year, marginally lower than the 3.9% predicted.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Equities

SNDK

USAR

Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet

U.S. stocks were lower, with the Dow Jones index falling over 900 points on Friday.
Shares of Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for its second quarter and issued upbeat FY25 <a href="https://www.benzinga.com/quote/SLP">earnings forecast</a>.
Simulations Plus reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $22.400 million which beat the analyst consensus estimate of $21.925 million.
Simulations Plus shares jumped 5.4% to $25.11 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) shares jumped 33.3% to $8.67.</li>
<li>Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) gained 11.8% to $9.55.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) surged 10.4% to $0.8200. XChange TEC.INC announced the acquisition of a Hong Kong-based insurance brokerage firm licensed by the Hong Kong Insurance Authority.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 6.8% to $25.95.</li>
<li>SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) gained 6% to $3.36.</li>
<li>Monro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) rose 5.5% to $15.27.</li>
<li>MarketAxess Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) gained 5% to $227.03 after the company announced trading volume statistics for march and first quarter.</li>
<li>Savers Value Village, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) rose 5% to $7.46. William Blair analyst Dylan Carden initiated coverage on Savers Value Village with an Outperform rating.</li>
<li>Columbia Sportswear Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) surged 3.4% to $69.48.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>
Photo via Shutterstock

ALMS

COLM

MKTX

MNRO

Simulations Plus Posts Better-Than-Expected Results, Joins Savers Value Village, MarketAxess Holdings And Other Big Stocks Moving Higher On Friday

U.S. stock futures declined on Friday after a bloodbath on Thursday following the introduction of President Donald Trump&#8216;s tariffs. Futures of major benchmark indices were lower in premarket trading.
Fueled by a broad market downturn, the Dow Jones plummeted by a staggering 1,679 points, its fifth-largest drop ever, while the S&amp;P 500 and Nasdaq suffered their biggest single-day losses since June and March 2020, respectively.
Trump, however, dismissed the tariff-induced selloff and said, &#8220;The market is going to boom, the stock is going to boom, the country is going to boom.&#8221;
The 10-year Treasury bond yielded 3.94% and the two-year bond was at 3.61%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in a 69.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.00%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.42%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 0.71% to $532.87, while the QQQ declined 0.62% to $447.85, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Technology sectors bore the brunt of Thursday&#8217;s U.S. stock market downturn. Specifically, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares plummeted approximately 9.3%, marking their steepest single-day decline since March 2020. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also saw a significant drop, tumbling 7.8%, while Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell by 8.98%. Across the broader market, consumer discretionary, energy, and information technology stocks registered the most substantial losses within the S&amp;P 500.
In contrast, consumer staples stocks stood out, bucking the prevailing negative trend and closing the session higher. This sector&#8217;s resilience was highlighted by Lamb Weston Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>), whose shares surged 10% after the company released third-quarter financial results that exceeded expectations and provided FY25 sales guidance above analyst estimates.
Economic data released Thursday presented a mixed picture. U.S. initial jobless claims decreased by 6,000 to 219,000 for the week ending March 29, falling below the anticipated 225,000. Additionally, the U.S. trade deficit narrowed to $122.7 billion in February, improving from $130.7 billion in January and slightly better than the forecasted $123.5 billion. However, the ISM services PMI declined to 50.8 in March, down from 53.5 in February and below market expectations of 53.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-5.97%</td>
<td>16,550.60</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-4.84%</td>
<td>5,396.52</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-3.98%</td>
<td>40,545.93</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-6.59%</td>
<td>1,910.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
CNBC&#8217;s Jim Cramer compared Trump&#8217;s tariffs to historical tariff regimes in the U.S., in an X post. he said, &#8220;It is not pro-tariff v. anti-tariff. It&#8217;s about accomplishing what&#8217;s good for our country while not having a Smoot-Hawley situation.&#8221;
The Smoot-Hawley Tariff Act, enacted in 1930, was a US law that significantly increased tariffs on imported goods, intended to protect American businesses and farmers, but ultimately worsened the Great Depression by triggering a global trade war.
However, he added that tariff-induced selloff on Thursday was &#8220;100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It is not pro-tariff v. anti-tariff. It&#39;s about accomplishing what&#39;s good for our country while not having a Smoot Hawley situation. Yesterday was 100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1908066366805991875?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
AQR Capital Management&#8217;s Chief Investment Officer, Cliff Asness, took to X on Thursday to voice his criticism of tariff proponents, specifically disputing the assertion that tariffs result in deflation instead of inflation.
His remarks were a direct response to Anthony Pompliano, the Founder &amp; CEO of Professional Capital Management and a well-known Bitcoin advocate, who had previously claimed, &#8220;Tariffs don't create inflation. The exact opposite happens."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Idiots say this and bray like they've scored a great point. What they mean is giant arbitrary tariffs are so bad they eventually cause recessions which then cause deflation. They then present this as a feature. And if they don't mean that they are even more wrong in some… <a href="https://t.co/ZihK0rbRU0">https://t.co/ZihK0rbRU0</a>
&mdash; Clifford Asness (@CliffordAsness) <a href="https://twitter.com/CliffordAsness/status/1907915579324760564?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Creative Planning&#8217;s chief market strategist, Charlie Bilello, noted that the VIX index reached its highest closing level since Aug. 5, 2024.
He suggested this increase in fear, coupled with lower stock prices, presents enhanced opportunities for investors with a long-term perspective. Bilello also pointed to historical trends, indicating that the S&amp;P 500 has historically delivered &#8220;higher than average&#8221; returns following significant surges in volatility.
He shared data showing that after a comparable spike on Aug. 5, 2024, the S&amp;P 500 returned 6% in one month, 11% in three months, and 18% over six months. On average, Bilello highlighted, the S&amp;P 500 has gained 12% six months after such volatility spikes and 21% after a year.
In an X post, Bilello summarized, &#8220;More Fear = More Opportunity.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24VIX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VIX</a> spiked nearly 40% higher today and closed above 30 for the first time since last August. What has happened in the past following the biggest volatility spikes? Higher than average forward S&amp;P 500 returns. More Fear = More Opportunity<a href="https://t.co/wMMGtwYloS">https://t.co/wMMGtwYloS</a> <a href="https://t.co/vVEN5vUBD1">pic.twitter.com/vVEN5vUBD1</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1907910013743722855?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>March&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Fed Chairman Jerome Powell will speak at 11:25 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Michael Barr will speak at 12:00 p.m. and Fed Governor Christopher Waller will speak at 12:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) was up 0.34% in premarket on Friday ahead of its earnings before the opening bell. Analysts expect a quarterly earnings of 1 cent per share on revenue of $7.70 million.</li>
</ul>
<ul>
<li>Neuroone Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) slumped 36.05% after the company disclosed a common stock public offering.</li>
</ul>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was up 2.50% after posting stronger-than-expected results for its second quarter and issuing an upbeat FY25 earnings forecast.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) surged 32.41% after announcing a new agreement with pharmaceutical giant Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.</li>
</ul>
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) jumped 3.98% after its CEO, Ryan Cohen, acquired 500,000 shares of the company.</li>
</ul>
<ul>
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) dropped 26.96% after the company said that it will enact a 1-for-10 reverse stock split effective Monday to meet Nasdaq&#8217;s bid price requirements.</li>
</ul>
<ul>
<li>Mullen Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) zoomed 83.64% after it stated that its U.S.-assembled Mullen and Bollinger commercial EV inventory is tariff-exempt.</li>
</ul>
<ul>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) gained 40.06% after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.57% to hover around $64.56 per barrel.
Gold Spot US Dollar declined 0.97% to hover around $3,083.92 per ounce. Its fresh record high stood at $3,168.04 per ounce. The U.S. Dollar Index spot was higher by 0.48% at the 102.564 level.
Asian markets closed on a lower note on Friday. India's S&amp;P BSE Sensex, Japan's Nikkei 225, Australia's ASX 200, China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi index fell. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44642317/sp-500-plummets-108-nasdaq-100-corrects-141-since-trumps-inauguration-heres-how-it-compares-to-obama-and-biden-eras">S&amp;P 500 Plummets 10.8%, Nasdaq 100 Corrects 14.1% Since Trump&#8217;s Inauguration: Here&#8217;s How It Compares To Obama And Biden Eras</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Futures

Economics

Federal Reserve

ETFs

AAPL

AMZN

BGLC

CXAI

MULN

NVDA

Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) to report quarterly earnings at 1 cent per share on revenue of $7.70 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Shared Hospital Services shares rose 0.3% to $2.97 in after-hours trading.</li>
<li>Guess? Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) reported upbeat results for its fourth quarter and named Alberto Toni as CFO. The company said it sees FY26 revenue to increase 3.9% &#8211; 6.2% in US Dollars and adjusted EPS of $1.32 &#8211; $1.76. Guess shares fell 2.4% to $9.80 in the after-hours trading session.</li>
<li>NeuroOne Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) disclosed a common stock public offering. NeuroOne Medical shares dipped 36.1% to $0.5499 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) posted stronger-than-expected results for its second quarter and issued upbeat FY25 earnings forecast. Simulations Plus shares gained 2.5% to $24.41 in the after-hours trading session.</li>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB. Sangamo Therapeutics shares jumped 47.7% to $0.9193 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Earnings Beats

Guidance

Simulations Plus Sees FY25 Adj. EPS $1.07-$1.20 Vs $0.47 Est; Revenue $90M-$93M Vs $90.445M Est

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.12 by 158.33 percent. This is a 55 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $22.400 million which beat the analyst consensus estimate of $21.925 million by 2.17 percent. This is a 22.37 percent increase over sales of $18.305 million the same period last year.

Simulations Plus Q2 2025 Adj. EPS $0.31 Beats $0.12 Estimate, Sales $22.400M Beat $21.925M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Lindsay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNN#NYSE">LNN</a>) is estimated to report quarterly earnings at $1.58 per share on revenue of $167.04 million. 
• MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is projected to report quarterly earnings at $0.68 per share on revenue of $899.59 million. 
• Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) is likely to report quarterly earnings at $0.89 per share on revenue of $1.50 billion. 
• Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $3.03 billion. 
• Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) is projected to report quarterly earnings at $3.61 per share on revenue of $950.32 million. 
• WisdomTree International LargeCap Dividend Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOL#NYSE">DOL</a>) is likely to report quarterly earnings at $1.31 per share on revenue of $1.84 billion. 
<h3>Companies Reporting After The Bell</h3>
• CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $2.00 million. 
• Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) is projected to report earnings for its third quarter. 
• Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) is estimated to report quarterly earnings at $1.86 per share on revenue of $84.63 billion. 
• Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is likely to report earnings for its second quarter. 
• Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is expected to report quarterly earnings at $1.43 per share on revenue of $920.92 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WisdomTree Trust International LargeCap Dividend

LFCR

Earnings Scheduled For April 3, 2025

Press Releases

Simulations Plus to Participate in the BTIG Digital Health Forum

Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

Simulations Plus to Participate in Upcoming Healthcare Investor Conferences

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

Comments

Simulations Plus

Simulations Plus (SLP) 옵션

Simulations Plus (NASDAQ:SLP) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌